

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Regis Healthcare Limited
ABN	11 125 203 054

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Linda Jane Mellors
Date of last notice	24 November 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of direct/indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Vesting and conversion of Rights granted to Dr Mellors by the Company pursuant to the 2021 Variable Reward and Retention Plan (VRRP) approved at the Annual General Meeting held on 26 October 2021. Upon vesting, Rights convert to Ordinary shares.
Date of change	26 September 2022
No. of securities held prior to change	158,000 Ordinary shares 76,893 Rights (unquoted)
Class	Ordinary shares
Number acquired	13,072 Ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	13,072 Rights (unquoted)
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	No cash consideration. Vesting of Rights issued to the Managing Director under the VRRP and conversion to Ordinary shares. No amount is payable on vesting or conversion.
No. of securities held after change	171,072 Ordinary shares 63,821 Rights (unquoted)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Vesting of Performance Rights granted to Dr Mellors by the Company pursuant to the 2021 Variable Reward and Retention Plan (VRRP) approved at the Annual General Meeting held on 26 October 2021 (subject to a continued employment condition)

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.